Qiuping Chen1, Linglong Fan1, Yunshu Xu1. 1. Department of Cardiology, Hangzhou Ninth People's Hospital Hangzhou 310000, Zhejiang, China.
Abstract
OBJECTIVE: To analyze the effects of metoprolol (MET) plus atorvastatin (ATO) on carotid intima-media thickness (IMT) and homocysteine (Hcy) level in carotid atherosclerosis (CAS) patients. METHODS: In this retrospective study, 90 patients with CAS admitted to the Hangzhou Ninth People's Hospital between January 2019 and July 2021 were enrolled, including 40 cases (control group, the Con) treated with MET and 50 cases treated with the combination therapy of MET plus ATO (Research group, the Res). The efficacy and related influencing factors were observed and compared. The clinical effects (IMT, plaque score), Hcy level, inflammatory cytokines (ICs; matrix metalloproteinase-9 [MMP-9], high-sensitivity C-reactive protein [hs-CRP]), blood lipid indices (low-/high- density lipoprotein cholesterol [LDL-C/HDL-C], total cholesterol [TC], triglyceride [TG]) and coagulation markers (thrombin time [TT], prothrombin time [PT], activated partial thromboplastin time [APTT], fibrinogen [FIB]) of the two groups were observed and compared. RESULTS: The results identified a statistically higher overall response rate in the Res group. Age, coronary heart disease, cerebral infarction and plaque score were confirmed to be closely related to the efficacy of CAS. In addition, statistically lower post-treatment IMT, plaque score, MMP-9, hs-CRP, LDL-C, TG, TC and FIB while higher PT, TT and APTT were determined in the Res group compared with the pre-treatment values and the Con group. CONCLUSIONS: MET plus ATO can significantly improve efficacy, reduce IMT and plaque score of patients with CAS, as well as improve inflammatory factors, blood lipid indices and coagulation markers, for which it deserves clinical promotion. AJTR
OBJECTIVE: To analyze the effects of metoprolol (MET) plus atorvastatin (ATO) on carotid intima-media thickness (IMT) and homocysteine (Hcy) level in carotid atherosclerosis (CAS) patients. METHODS: In this retrospective study, 90 patients with CAS admitted to the Hangzhou Ninth People's Hospital between January 2019 and July 2021 were enrolled, including 40 cases (control group, the Con) treated with MET and 50 cases treated with the combination therapy of MET plus ATO (Research group, the Res). The efficacy and related influencing factors were observed and compared. The clinical effects (IMT, plaque score), Hcy level, inflammatory cytokines (ICs; matrix metalloproteinase-9 [MMP-9], high-sensitivity C-reactive protein [hs-CRP]), blood lipid indices (low-/high- density lipoprotein cholesterol [LDL-C/HDL-C], total cholesterol [TC], triglyceride [TG]) and coagulation markers (thrombin time [TT], prothrombin time [PT], activated partial thromboplastin time [APTT], fibrinogen [FIB]) of the two groups were observed and compared. RESULTS: The results identified a statistically higher overall response rate in the Res group. Age, coronary heart disease, cerebral infarction and plaque score were confirmed to be closely related to the efficacy of CAS. In addition, statistically lower post-treatment IMT, plaque score, MMP-9, hs-CRP, LDL-C, TG, TC and FIB while higher PT, TT and APTT were determined in the Res group compared with the pre-treatment values and the Con group. CONCLUSIONS: MET plus ATO can significantly improve efficacy, reduce IMT and plaque score of patients with CAS, as well as improve inflammatory factors, blood lipid indices and coagulation markers, for which it deserves clinical promotion. AJTR
Authors: Hiurma Sánchez-Pérez; Juan Carlos Quevedo-Abeledo; Laura de Armas-Rillo; Íñigo Rua-Figueroa; Beatriz Tejera-Segura; Estefanía Armas-González; José David Machado; Jose A García-Dopico; Alejandro Jimenez-Sosa; Carlos Rodríguez-Lozano; Federico Díaz-González; Miguel A González-Gay; Iván Ferraz-Amaro Journal: Rheumatology (Oxford) Date: 2020-10-01 Impact factor: 7.580
Authors: Chen Liang; Li Xiaonan; Cai Xiaojun; Li Changjiang; Xu Xinsheng; Jiang Guihua; Hu Xiaobo; Zhang Yanen; Su Runyi; Lu Huixia; Zhang Yun; Zhang Mei Journal: Eur J Pharmacol Date: 2009-04-06 Impact factor: 4.432
Authors: Binh An P Phan; Bernard Weigel; Yifei Ma; Rebecca Scherzer; Danny Li; Sophia Hur; S C Kalapus; Steven Deeks; Priscilla Hsue Journal: Circ Cardiovasc Imaging Date: 2017-07 Impact factor: 7.792
Authors: Rasmus Rivinius; Matthias Helmschrott; Ann-Kathrin Rahm; Fabrice F Darche; Dierk Thomas; Tom Bruckner; Andreas O Doesch; Hugo A Katus; Philipp Ehlermann Journal: Clin Res Cardiol Date: 2020-06-22 Impact factor: 5.460